S1384 Exit Interviews Exploring Patients' Experience of Changes in Their Fatigue During the Phase 3 Clinical Trial of Mirikizumab for Treatment of Moderately to Severely Active Crohn's Disease

Theresa Gibble,Jake Macey,Harriet Makin,Rodica Rosu,Katie Mellor,Helen Kitchen,Emily Hon,Aisha Vadhariya,Sylvia Su,Miguel D Regueiro
DOI: https://doi.org/10.14309/01.ajg.0001034904.32982.54
2024-10-26
The American Journal of Gastroenterology
Abstract:Fatigue is a common and debilitating symptom of Crohn's disease (CD), associated with functional impairment and reduced quality of life. Here we qualitatively explore change in fatigue in participants with moderately to severely active CD who completed the phase 3, randomised, double-blind, placebo- and active-controlled, mirikizumab clinical trial (VIVID-1).
gastroenterology & hepatology
What problem does this paper attempt to address?